Stocks
Editas Medicine, Inc.EDIT
NASDAQHealthcareBiotechnology$2.44-3.94%
A clinical-stage biotechnology company developing gene-editing therapies using CRISPR/Cas9 and related technologies to treat inherited diseases. Its pipeline includes experimental treatments for genetic disorders, with research spanning ophthalmology, hematology, and other areas. Investors monitor t...
Market Cap: $238.8M52W Range: $0.91 – $4.54
Congressional Interest in Editas Medicine, Inc. (EDIT)
6 members of Congress have disclosed 21 trades in Editas Medicine, Inc. (EDIT), a Healthcare company. The buy/sell breakdown shows 11 purchases versus 10 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
21
Unique Politicians
6
Buys
11
Sells
10
Who in Congress Is Trading EDIT?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2023-04-10 | Daniel Goldman | sell | $1K – $15K |
| 2021-04-14 | Donald Sternoff Beyer | sell | $1K – $15K |